Genetic, hormonal and metabolic aspects of PCOS: An update

Reproductive Biology and Endocrinology

Volumn 14, Issue 1, 2016, Pages

  De Leo, V ^a   Musacchio, M C ^a   Cappelli, V ^a   Massaro, M G ^a   Morgante, G ^a   Petraglia, F ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Genetic; Hyperandrogenism; Infertility; Insulin resistance; Metformin; Myo inositol; Oral contraceptives; PCOS

Indexed keywords

ACTIVIN; FAS ANTIGEN; FAS LIGAND; FOLLISTATIN; FOLLITROPIN; GONADORELIN; GONADOTROPIN; GROWTH FACTOR; HEAT SHOCK PROTEIN; HOMOCYSTEINE; HORMONE; INHIBIN; INTERLEUKIN DERIVATIVE; LEPTIN; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; NEUROTROPHIN GROWTH FACTOR; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; SEX HORMONE;

ACNE; ALOPECIA; ANOVULATION; CARBOHYDRATE METABOLISM; CLINICAL FEATURE; ECHOGRAPHY; ENVIRONMENTAL FACTOR; EPIGENETICS; GENETIC ASSOCIATION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSULIN RESISTANCE; LIPID METABOLISM; MENOPAUSE; METABOLISM; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PROTEIN METABOLISM; REVIEW; ANIMAL; FEMALE; GENETIC EPIGENESIS; OBESITY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME;

ANIMALS; EPIGENESIS, GENETIC; FEMALE; GONADAL STEROID HORMONES; HIRSUTISM; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 84978280253     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/s12958-016-0173-x     Document Type: Review

References (113)

1. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
2. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. p. 377-84.
3. Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess guideline. J Clin Endocrinol Metab. 2006;91:4237-45.
4. Franks S, Mc Carthy M, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006;29:278-85.
5. De Leo V, La Marca A. Petraglia F Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003;24:633-67.
6. Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, Grayson K. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013;28:1077-83.
7. Lam PM, Raine-Fenning N. The role of three-dimensional ultrasonography in polycystic ovary syndrome. Hum Reprod. 2006;21:2209-15.
8. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome-a hypothesis. J Endocrinol. 2002;174:1-5.
9. Maliqueo M, Lara HE, Sanchez F, Echiburu B, Crisosto N, Sir-Petermann T. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;166:151-5.
10. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod. 2002;17:2573-9.
11. Jones ME, Boon WC, McInnes K, Maffei L, Carani C, Simpson ER. Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab. 2007;3:414-21.
12. Hertig A, Liere P, Chabbert-Buffet N, Fort J, Pianos A, Eychenne B, et al. Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol. 2010;203:477-9.
13. Jobe SO, Tyler CT, Magness RR. Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular dysfunction. Hypertension. 2013;61:480-7.
14. Mehrabian F, Kelishadi R. Comparison of the metabolic parameters and androgen level of umbilical cord blood in newborns of mothers with polycystic ovary syndrome and controls. J Res Med Sci. 2012;17:207-11.
15. Barry JA, Kay AR, Navaratnarajah R, Iqbal S, Bamfo JE, David AL, et al. Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J Obstet Gynaecol. 2010;30:444-6.
16. Anderson H, Fogel N, Grebe SK, Singh RJ, Taylor RL, Dunaif A. Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J Clin Endocrinol Metab. 2010;95:2180-6.
17. Hickey M, Sloboda DM, Atkinson HC, Doherty DA, Franks S, Norman RJ, et al. The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J Clin Endocrinol Metab. 2009;94:3714-20.
18. Beck-Peccoz P, Padmanabhan V, Baggiani AM, Cortelazzi D, Buscaglia M, Medri G, et al. Maturation of hypothalamic-pituitary-gonadal function in normal human fetuses: circulating levels of gonadotropins, their common alpha-subunit and free testosterone, and discrepancy between immunological and biological activities of circulating follicle-stimulating hormone. J Clin Endocrinol Metab. 1991;73:525-32.
19. Cole B, Hensinger K, Maciel GA, Chang RJ, Erickson GF. Human fetal ovary development involves the spatiotemporal expression of p450c17 protein. J Clin Endocrinol Metab. 2006;91:3654-61.
20. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, Sloboda DM. Serum antim€ullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010;94:1118-21.
21. Sir-Petermann T, Codner E, Perez V, Echiburu B, Maliqueo M, Ladron de Guevara A, et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:1923-30.
22. Crisosto N, Echiburu B, Maliqueo M, Perez V, Ladron de Guevara A, Preisler J, et al. Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. Fertil Steril. 2012;97:218-24.
23. Sir-Petermann T, Ladron de Guevara A, Codner E, Preisler J, Crisosto N, Echiburu B, et al. Relationship between anti-Mullerian hormone (AMH) and insulin levels during different Tanner stages in daughters of women with polycystic ovary syndrome. Reprod Sci. 2012;19:383-90.
24. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2001;138:38-44.
25. Maliqueo M, Sir-Petermann T, Perez V, Echiburu B, de Guevara AL, Galvez C, et al. Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:3282-8.
26. Rosenfield RL. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol. 2001;45:95-104.
27. Jabbar M, Pugliese M, Fort P, Recker B, Lifshitz F. Excess weight and precocious pubarche in children: alterations of the adrenocortical hormones. J Am Coll Nutr. 1991;10:289-96.
28. Apter D, Butzow T, Laughlin GA, Yen SS. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab. 1995;80:2966-73.
29. McCartney CR, Prendergast KA, Blank SK, Helm KD, Chhabra S, Marshall JC. Maturation of luteinizing hormone (gonadotropin-releasing hormone) secretion across puberty: evidence for altered regulation in obese peripubertal girls. J Clin Endocrinol Metab. 2009;94:56-66.
30. Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res. 2010;1364:186-97.
31. Burt Solorzano CM, McCartney CR, Blank SK, Knudsen KL, Marshall JC. Hyperandrogenaemia in adolescent girls: origins of abnormal gonadotropinreleasing hormone secretion. BJOG. 2010;117:143-9.
32. Blank SK, McCartney CR, Chhabra S, Helm KD, Eagleson CA, Chang RJ, et al. Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls-implications for regulation of pubertal maturation. J Clin Endocrinol Metab. 2009;94:2360-6.
33. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (noninsulin- dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62-7.
34. Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br Med Bull. 2001;60:5-20.
35. Jaquet D, Leger J, Czernichow P, Levy-Marchal C. The effect of in-utero undernutrition on the insulin resistance syndrome. Curr Diabetes Rep. 2002;2:77-82.
36. Leger J, Levy-Marchal C, Bloch J, Pinet A, Chevenne D, Porquet D, et al. Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. BMJ. 1997;315:341-7.
37. Jaquet D, Tregouet DA, Godefroy T, Nicaud V, Chevenne D, Tiret L, et al. Combined effects of genetic and environmental factors on insulin resistance associated with reduced fetal growth. Diabetes. 2002;51:3473-8.
38. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. Diabetes Care. 1995;18:611-7.
39. Silverman BL, Rizzo TA, Cho NH, Metzger BE. Northwestern University Diabetes in Pregnancy Center. Long-term effects of the intrauterine environment. Diabetes Care. 1998;21:142-9.
40. Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes. 2000;49:2208-11.
41. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999;20:535-82.
42. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab. 1996;81:881-6.
43. Franks S, McCarthy M. Genetics of ovarian disorders: polycystic ovary syndrome. Rev Endocr Metab Disord. 2004;5:69-76.
44. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43:55-9.
45. Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, Chen YD, et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet. 2012;49:90-5.
46. Welt CK, Styrkarsdottir U, Ehrmann DA, Thorleifsson G, Arason G, Gudmundsson JA, et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012;97:1342-7.
47. Xie GB, Xu P, Che YN, Xia YJ, Cao YX, Wang WJ, et al. Microsatellite polymorphism in the fibrillin 3 gene and susceptibility to PCOS: a case-control study and meta-analysis. Reprod Biomed Online. 2013;26:168-74.
48. Capalbo A, Sagnella F, Apa R, Fulghesu AM, Lanzone A, Morciano A, et al. The 312N variant of the luteinizing hormone/choriogonadotropin receptor gene (LHCGR) confers up to 2.7-fold increased risk of polycystic ovary syndrome in a Sardinian population. Clin Endocrinol (Oxf). 2012;77:113-9.
49. Mutharasan P, Galdones E. Pe~nalver Bernabe B, Garcia OA, Jafari N, Shea LD, et al. Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestry. J Clin Endocrinol Metab. 2013;98:E185-90.
50. Urbanek M, Sam S, Legro RS, Dunaif A. Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab. 2007;92:4191-8.
51. Hatzirodos N, Bayne RA, Irving-Rodgers HF, Hummitzsch K, Sabatier L, Lee S, et al. Linkage of regulators of TGF-b activity in the fetal ovary to polycystic ovary syndrome. FASEB J. 2011;25:2256-65.
52. Sabatier L, Miosge N, Hubmacher D, Lin G, Davis EC, Reinhardt DP. Fibrillin-3 expression in human development. Matrix Biol. 2011;30:43-52.
53. Xu N, Kwon S, Abbott DH, Geller DH, Dumesic DA, Azziz R, et al. Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS One. 2011;6:e27286.
54. Massam-Wu T, Chiu M, Choudhury R, Chaudhry SS, Baldwin AK, McGovern A, et al. Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta. J Cell Sci. 2010;123:3006-18.
55. Sengle G, Ono RN, Sasaki T, Sakai LY. Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J Biol Chem. 2011;286:5087-99.
56. Dickinson RE, Stewart AJ, Myers M, Millar RP, Duncan WC. Differential expression and functional Characterization of luteinizing hormone receptor splice variants in human luteal cells:implications for luteolysis. Endocrinology. 2009;150(6):2873-81.
57. Dos Santos E, Dievdonnè MN, Leneveu MC, Pecquery R, Serazin V, Giudicelli Y. In vitro effects of chorionic gonadotrophin hormone on human adipose development. J Endocrinol. 2007;194(2):313-25.
58. Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26:251-82.
59. Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2011;17:17-33.
60. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820-5.
61. THOMSON RL, SPEDDING S, BUCKLEY JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol. 2012;77:343-50.
62. Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin HG, Kamaci M. Serum 25-hydroxy vitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280:559-63.
63. Kalro BN, Loucks TL, Berga SL. Neuromodulation in polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2001;28:35-62.
64. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008;14:367-78.
65. Oakley AE, Clifton DK, Steiner RA. Kisspeptin signaling in the brain. Endocr Rev. 2009;30:713-43.
66. D'Anglemont de Tassigny X, Colledge WH. The role of kisspeptin signaling in reproduction. Physiology (Bethesda). 2010;25:207-17.
67. Navarro VM, Tena-Sempere M. Neuroendocrine control by kisspeptins: role in metabolic regulation of fertility. Nat Rev Endocrinol. 2012;8:40-53.
68. Pinilla L, Aguilar E, Dieguez C, Millar RP, Tena-Sempere M. Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev. 2012;92:1235-316.
69. Castellano JM, Gaytan M, Roa J, Vigo E, Navarro VM, Bellido C, et al. Expression of Kiss-1 in rat ovary: putative local regulator of ovulation? Endocrinology. 2006;147:4852-62.
70. Gaytan F, Gaytan M, Castellano JM, Romero M, Roa J, Aparicio B, et al. Kiss-1 in the mammalian ovary: distribution of kisspeptin in human and marmoset and alterations in Kiss-1 mRNA levels in a rat model of ovulatory dysfunction. Am J Physiol Endocrinol Metab. 2009;296:5520-31.
71. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10:1-21.
72. La Marca A, Egbe TO, Morgante G, Paglia T, Cianci A, De Leo V. Metformin treatment reduces ovarian cytochrome P-450c17 response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod. 2000;15:21-3.
73. Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism of hyperandrogenemia and insulin resistance. Fertil Steril. 2008;89:1039-48.
74. Diamanti-Kandarakis E, Argyrakopolou G, Economou F, et al. Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome. J Steroid Biochem an Molecular Bio. 2008;109:242-6.
75. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83:2001-5.
76. Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositol metabolism. Hum Reprod. 2008;23:1439-46.
77. De Leo V, La Marca A, Orvieto R, Morgante G. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J Clin Endocrinol Metab. 2000;85:1598-600.
78. Artini PG, Monteleone P, Toldin MRP, Matteucci C, Ruggiero M, Cela V, Genazzani AR. Growth factors and folliculogenesis in polycystic ovary patients. Expert Rev Endocrinol Metab. 2007;2:215-23.
79. Dumesic DA, Abbott DH. Implications of polycystic ovary syndrome on oocyte development. Seminar Reprod Med. 2008;26:53-61.
80. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2009;16:113-30.
81. Corton M, Botella-Carretero JI, Lopez JA, Camafeita E, San Millan JL, Escobar- Morreale HF, Peral B. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Hum Reprod. 2008;23:651-61.
82. Ma X, Fan L, Meng Y, Hou Z, Mao YD, Wang W, Ding W, Liu JY. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol Hum Reprod. 2007;13:527-35.
83. Choi DH, Lee WS, Won M, Park M, Park HO, Kim E, Lee KA, Bae J. The apolipoprotein A-I level is downregulated in the granulosa cells of patients with polycystic ovary syndrome and affects steroidogenesis. J Proteome Res. 2010;9:4329-36.
84. Huang S, Qiao J, Li R, Wang L, Li M. Can serum apolipoprotein C-I demonstrate metabolic abnormality early in women with polycystic ovary syndrome? Fertil Steril. 2010;9:205-10.
85. Ilhan A, Gartner W, Nabokikh A, Daneva T, Majdic O, Cohen G, Bohmig GA, Base W, Horl WH, Wagner L. Localization and characterization of the novel protein encoded by C20orf3. Biochem J. 2008;414:485-95.
86. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013;19:268-88.
87. Bi X, Haque TS, Zhou J, Skillman AG, Lin B, Lee CE, Kuntz ID, Ellman JA, Lynch G. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus. J Neurochem. 2000;74:1469-77.
88. Vashishta A, Ohri SS, Vetvicka V. Pleiotropic effects of cathepsin D. Endocr Metab Immune Disord Drug Targets. 2009;9:385-91.
89. Misiti S, Stigliano A, Borro M, Gentile G, Michienzi S, Cerquetti L, Bucci B, Argese N, Brunetti E, Simmaco M, Toscano V. Proteomic profiles in hyperandrogenic syndromes. J Endocrinol Invest. 2010;33:156-64.
90. Fan L, Ling J, Ma X, Cui YG, Liu JY. Involvement of HSP10 during the ovarian follicular development of polycystic ovary syndrome: Study in both human ovaries and cultured mouse follicles. Gynecol Endocrinol. 2009;25:392-7.
91. Chazenbalk G, Chen YH, Heneidi S, Lee JM, Pall M, Chen YD, Azziz R. Abnormal expression of genes involved in inflammation, lipid metabolism, and Wnt signaling in the adipose tissue of polycystic ovary syndrome. J Clin Endocrinol Metab. 2012;97:E765-70.
92. Insenser M, Martinez-Garcia MA, Montes R, San-Millan JL, Escobar-Morreale HF. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. J Clin Endocrinol Metab. 2010;95:3863-70.
93. Escobar-Morreale HF. Iron metabolism and the polycystic ovary syndrome. Trends Endocrinol Metab. 2012;23:509-15.
94. Luque-Ramirez M, Alvarez-Blasco F, Alpanes M, Escobar-Morreale HF. Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96:846-52.
95. Victor VM, Rocha M, Banuls C, Alvarez A, de Pablo C, Sanchez-Serrano M, Gomez M, Hernandez-Mijares A. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2011;96:3115-22.
96. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen speciesinduced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:336-40.
97. Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod. 2007;22:1200-9.
98. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod. 2000;15:24-8.
99. Bekx MT, Connor EC, Allen DB. Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovarian syndrome. J Pediatr Adolesc Gynecol. 2010;23:7-10.
100. Ardaens Y, Robert Y, Lemaitre L, Fossati P, Dewailly D. Polycystic ovary disease: contribution of vaginal endosonography and reassessment of ultrasonic diagnosis. Fertil Steril. 1991;55:1062-8.
101. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440-7.
102. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21:363-92.
103. Carmina E, Oberfeld S, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203:201.e1-5.
104. Hudecova M, Holte J, Olovsson M, Sundstrom PI. Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Hum Reprod. 2009;24:1176-83.
105. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84:1897-9.
106. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;66:513-7.
107. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycyatic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:748-58.
108. Boosma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:673-83.
109. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome. Hum Reprod Update. 2005;11:357-74.
110. Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical and genetic association studies. J Clin Endocrinol Metab. 2006;91:1660-6.
111. Giudice LC. Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab. 2006;20:235-44.
112. Denison FC, Roberts KA, Barr SM, Norman JE. Obesity, pregnancy, inflammation and vascular function. Reproduction. 2010;24:112-45.
113. Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet. 2005;365:1807-16.